http://www.nature.com/news/seven-days-3-9-august-2012-1.11139
Alzheimer’s setback Research has been halted on a keenly watched experimental drug aimed at treating Alzheimer’s disease after it failed two late-stage clinical trials. Pharmaceutical companies Johnson & Johnson, based in New Brunswick, New Jersey, and Pfizer, based in Groton, Connecticut, said on 6 August that they would no longer work on the monoclonal antibody bapineuzumab. It binds a peptide, amyloid-β, that may cause neurodegeneration in patients with Alzheimer’s. But in two phase III trials — one reported on 23 July and one on 6 August — the drug did not prevent cognitive decline.
No comments:
Post a Comment